Puriblood Medical Co., Ltd. (6847) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Puriblood Medical Co., Ltd. stock TWD 51.13, price TWD 71.10, that is 28.1% below the price, quality 44 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
11‑month range 47.85 TWD – 88.70 TWD · fair‑value band 33.87 TWD – 64.15 TWD · the 71.10 TWD price screens above the 51.13 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Puriblood Medical Co. in your weekly email
Every Wednesday you see whether Puriblood Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula.
Show moreShow less
It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.
Stock analysis
Puriblood Medical Co., Ltd. (6847) currently trades at 71.10 TWD, while our model-based Fair Value estimate is 51.13 TWD, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 33.87 TWD (bear) to 64.15 TWD (bull), the price of 71.10 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Puriblood Medical Co., Ltd. reported revenue of 82.3M TWD in FY2025 versus 54.6M TWD in FY2021, a compound +10.8%/yr. Reported net income was −39.0M TWD in FY2025.
Key figures
Market cap 1.2B TWD (≈ $37.2M) Micro · P/S ratio 15.3 · EPS (TTM) −3.89 TWD · Net margin −69.3% · Return on equity −40.9% · Return on assets (EBIT) −9.0% (5-year average) · Operating margin −64.2% · Revenue (TTM) 80.5M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −28%, 6847 screens richer than that median.
Fair Value models
Bear33.87 TWDFair Value 51.13 TWDBull64.15 TWD
Price 71.10 TWD · Downside -28.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−25.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.5% (2020) → −40.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Puriblood Medical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−28.1% · Above median
Profitability
Return on assets−16.5% · Bottom 25%
Net margin (12 months)−69.3% · Bottom 25%
Operating margin (12 months)−64.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−4.5% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B8.71× · Priciest 25%
P/S (12 months)15.17× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 39
PAST (return on equity)0· sector 15
HEALTH (low debt)93· sector 95
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Puriblood Medical Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6847
Frequently asked questions
Is Puriblood Medical Co., Ltd. (6847) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 51.13 TWD versus a price of 71.10 TWD, about 28% lower (overvalued).
What is the fair value of 6847?
Our model-based fair value for Puriblood Medical Co., Ltd. is 51.13 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 71.10 TWD.
What is the quality score of 6847?
Puriblood Medical Co., Ltd. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Puriblood Medical Co., Ltd. (6847)?
Our model-based price target is the fair value of 51.13 TWD (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 33.87 TWD, optimistic scenario 64.15 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Puriblood Medical Co., Ltd. stock forecast for 2026?
Our models put fair value at 51.13 TWD, about 28% lower versus a price of 71.10 TWD (overvalued). Cautious scenario 33.87 TWD, optimistic scenario 64.15 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Puriblood Medical Co., Ltd. (6847)?
Puriblood Medical Co., Ltd. reported trailing-twelve-month revenue of about 80.5M TWD (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Puriblood Medical Co., Ltd. (6847)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Puriblood Medical Co., Ltd. it is 51.13 TWD per share (as of Nov 3, 2026), against a price of 71.10 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Puriblood Medical Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6847 trades above its calculated fair value: price 71.10 TWD, fair value 51.13 TWD, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6847?
No. The price is what the market pays today (71.10 TWD); the fair value is what the company's own numbers justify (51.13 TWD). For Puriblood Medical Co., Ltd. the two are 19.97 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Puriblood Medical Co., Ltd. worth?
The market values Puriblood Medical Co., Ltd. at about 1.2B TWD (market capitalisation, as of Nov 3, 2026). Per share that is 71.10 TWD; our models calculate a fair value of 51.13 TWD per share.
What do the bullish and bearish scenarios say about 6847?
Our models span a range for Puriblood Medical Co., Ltd.: cautious scenario 33.87 TWD, base 51.13 TWD, optimistic 64.15 TWD per share (as of Nov 3, 2026, price 71.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Puriblood Medical Co., Ltd. (6847)?
Balance-sheet figures for Puriblood Medical Co., Ltd. (as of Nov 3, 2026): return on equity −40.9%, debt of 0.13 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6847 from its 52-week high?
Puriblood Medical Co., Ltd. trades at 71.10 TWD, about 20% below its 52-week high of 88.70 TWD and 49% above the low of 47.85 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 51.13 TWD is for.
Which stocks are comparable to Puriblood Medical Co., Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Puriblood Medical Co., Ltd. stock attractive at the current price?
The data as of Nov 3, 2026: price 71.10 TWD, calculated fair value 51.13 TWD (−28%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6847 calculated?
We run Puriblood Medical Co., Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 51.13 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Puriblood Medical Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Puriblood Medical Co., Ltd. (6847)?
The closing price on Nov 6, 2026 was 71.10 TWD. Our model-based fair value is 51.13 TWD, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Puriblood Medical Co., Ltd. right now?
The price sits above even our optimistic bull case (64.15 TWD). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (33.87 TWD to 64.15 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Puriblood Medical Co., Ltd.
How large is the market capitalisation of Puriblood Medical Co., Ltd. (6847)?
The market capitalisation of Puriblood Medical Co., Ltd. is 1.2B TWD (≈ $37.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Puriblood Medical Co., Ltd. (6847)?
The price-to-sales ratio of Puriblood Medical Co., Ltd. is 15.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Puriblood Medical Co., Ltd. (6847)?
Earnings per share at Puriblood Medical Co., Ltd. are −3.89 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Puriblood Medical Co., Ltd. (6847)?
The net margin of Puriblood Medical Co., Ltd. is −69.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Puriblood Medical Co., Ltd. (6847)?
The return on equity (ROE) of Puriblood Medical Co., Ltd. is −40.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Puriblood Medical Co., Ltd. (6847)?
On an EBIT basis the return on assets of Puriblood Medical Co., Ltd. is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Puriblood Medical Co., Ltd. (6847)?
The operating margin of Puriblood Medical Co., Ltd. is −64.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Puriblood Medical Co., Ltd. (6847)?
Revenue at Puriblood Medical Co., Ltd. is growing −4.5% versus a year earlier (3y avg −15.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Puriblood Medical Co., Ltd. (6847) generate?
The free cash flow of Puriblood Medical Co., Ltd. is −27.9M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Puriblood Medical Co., Ltd. (6847) hold?
Puriblood Medical Co., Ltd. holds more cash than debt, 34.8M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Puriblood Medical Co., Ltd. in the live analysis
One click puts Puriblood Medical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026